Preclinical
[용어속성] Term
Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2
Article
[키워드] acute respiratory syndrome
amino acid substitution
amubarvimab (BRII-196)
antibody
antibody cocktail
Clinical efficacy
Combination
controls
coronavirus
coronavirus disease
COVID-19
demonstrated
Emergency use authorization
epitope
EUA
Evolution
half-maximal inhibitory concentration
half-maximal inhibitory concentration (IC50)
in vitro
introduced
less
Lung pathology
Lungs
M252Y/S254T/T256E (YTE)
mAb
mAbs
Modification
monoclonal antibody
monoclonal antibody (mAb)
Mutation
neutralize
neutralized
Neutralizing
Post-infection
Preclinical
RBD
receiving
Receptor binding domain
receptor binding domain (RBD)
reduce
reduced
regions
regulatory authority
resulting
retained
romlusevimab (BRII-198)
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 variants
serum
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
significantly
Spike protein
Support
susceptibility
therapeutic option
variant
variant of concern (VOC)
variants
variants of concern
Viral load
virus
VoC
weight loss
[DOI] 10.3389/fimmu.2022.980435 PMC 바로가기
[DOI] 10.3389/fimmu.2022.980435 PMC 바로가기
Influence of Effort-based Reward Training on Neuroadaptive Cognitive Responses: Implications for Preclinical Behavioral Approaches for Depressive Symptoms
Research article
[키워드] approach
approaches
assigned
BDNF
brain-derived neurotrophic factor (BDNF)
cognitive
Dehydroepiandrosterone (DHEA)
depressive
depressive symptom
Depressive symptoms
disorder
Efficacy
Effort-based Reward (EBR)
examination
exhibited
faster
female
group
immunoreactivity
incidence rate
influence
lack
Lateral habenula (LHb)
male
males
mechanism
mechanisms
no significant effect
offer
Preclinical
Preclinical model of depression
prevented
provide
response
therapeutic intervention
Therapies
training
Trial
trials
were assessed
[DOI] 10.1016/j.neuroscience.2022.08.002 [Article Type] Research article
[DOI] 10.1016/j.neuroscience.2022.08.002 [Article Type] Research article
Cell-Based Platform for Antigen Testing and Its Application for SARS-CoV-2 Infection
Article
[키워드] active infection
acute respiratory syndrome
amplification
Antigen
antigen test
applicability
application
asymptomatic individual
Calu-3
can be used
CAR
CAR T-cell
Care
Cell
cell line
cell-based sensors
characterized
Community
competent
conducted
control sample
coronavirus
COVID-19
COVID-19 diagnostics
detect
diagnosing
effective
facilitate
function
Health
host cell
implementation
individual
infected with SARS-CoV-2
Infection
infections
lack
mice
molecular
mRNA
offer
oropharyngeal swab
pandemic
Pandemics
PCR
platform
Preclinical
present antigen
qPCR
quantitative PCR
reporter
reporter cell.
robust
SARS-CoV-2
Signaling
specificity
spike glycoprotein
symptomatic
target pathogen
tested
Testing
viruses
Volume
[DOI] 10.1128/spectrum.00731-22 PMC 바로가기
[DOI] 10.1128/spectrum.00731-22 PMC 바로가기
Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera
수포성 구내염 바이러스-SARS-CoV-2 키메라 기반 코로나19 후보 백신의 전임상 면역원성과 효능
Article
[키워드] acute respiratory syndrome
administration
AIDS
approach
authority
candidate vaccine
chimeric
coding sequence
coronavirus
coronavirus disease
cotton
Cotton rat
COVID-19
COVID-19 vaccine
Department
develop
development
dose
Ebola virus
Efficacy
evaluated
glycoprotein
hamster
hamsters
Immunity
immunogenic
immunogenicity
Inc
Inc.
initiative
injection
intramuscular
lung
mucosal
Mucosal vaccination
nasal
nasal tissue
New York
Part
Preclinical
PROTECT
reduce
reduced
replacing
Research
respond
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 replication
SARS-CoV-2 vaccine
Sharp
significantly
single vaccine
spike
stomatitis
supported
Syrian hamster
the SARS-CoV-2
the vaccine
threat
tissues
Transmission
USA
vaccination
Vaccine
vaccine candidate
vesicular stomatitis
vesicular stomatitis virus
virus
virus load
VSV
weight loss
[DOI] 10.1016/j.ebiom.2022.104203 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.ebiom.2022.104203 PMC 바로가기 [Article Type] Article
Tissue repair strategies: What we have learned from COVID-19 in the application of MSCs therapy
Review article
[키워드] ACE2angiotensin converting enzyme 2
acute lung injury
acute respiratory distress syndrome
adverse outcome
ALIacute lung injury
alveolar type 2 cells
angiotensin converting enzyme 2
ARDSacute respiratory distress syndrome
AstraZeneca
AT2salveolar type 2 cells
ataxia telangiectasia and Rad3-related
ATRataxia telangiectasia and Rad3-related
BDNFbrain derived neurotrophic factor
brain derived neurotrophic factor
BRDbromodomain protein
bromodomain protein
C-reactive protein
CCNG1Cyclin G1
CD147cluster of differentiation 147
Cell
Clinical finding
cluster of differentiation 147
confirmed case
Coronavirus disease 2019
COVID-19
COVID-19 pandemic
COVID-19 patients
COVID-19coronavirus disease 2019
CRPC-reactive protein
Cyclin G1
Cytokine storm
DRP1dynamin-related protein 1
dynamin-related protein 1
ECMOextracorporeal membrane oxygenation
effective
EGFepidermal growth factor
Emergency use authorization
epidermal growth factor
EUAemergency use authorization
EVsextracellular vesicles
example
exhibited
Extracellular vesicles
extracorporeal membrane oxygenation
FGFfibroblast growth factor
fibroblast growth factor
galanin and gmap prepropeptide
GALgalanin and gmap prepropeptide
GM-CSFgranulocyte macrophage-colony stimulating factor
granulocyte macrophage-colony stimulating factor
HBVHepatitis B virus
Heme oxygenase-1
Hepatitis B virus
hepatocyte growth factor
hESCshuman embryonic stem cells
HGFhepatocyte growth factor
hiPSCshuman induced PSCs
HIVhuman immunodeficiency virus
HO-1heme oxygenase-1
hPSC-CMshPSC-derived cardiomyocytes
hPSC-derived cardiomyocytes
hPSCshuman pluripotent stem cells
human embryonic stem cells
Human immunodeficiency virus
human induced PSCs
human pluripotent stem cells
Hyperinflammatory syndrome
IFN-βinterferon-β
IFN-γinterferon-γ
IFN-λinterferon-λ
IGF1Rinsulin like growth factor 1 receptor
Infection
insulin like growth factor 1 receptor
Intensive
Interferon-β
interferon-γ
interferon-λ
keratinocyte growth factor-2
KGF2keratinocyte growth factor-2
leukemia inhibitory factor
LIFleukemia inhibitory factor
management
MECP2methyl-CpG binding protein 2
Mesenchymal stem cells
methyl-CpG binding protein 2
Microvesicles
Moderna
Mortality
MSCs
MSCs therapy
MSCsmesenchymal stem cells
MVsmicrovesicles
National Institutes of Health
nerve growth factor
NGFnerve growth factor
NIHNational Institutes of Health
nitric oxide associated 1
NLR family pyrin domain containing 3
NLRP3NLR family pyrin domain containing 3
NOA1nitric oxide associated 1
organ damage
organ injury
P4HA1prolyl 4-hydroxylase subunit alpha 1
PDGFplatelet-derived growth factor
Pfizer
PGE2prostaglandin E2
phosphatase and tensin homolog
platelet-derived growth factor
Preclinical
Preferred reporting items for systematic reviews and meta-analyses
PRISMAPreferred reporting items for systematic reviews and meta-analyses
proinflammatory
prolyl 4-hydroxylase subunit alpha 1
prostaglandin E2
PTENphosphatase and tensin homolog
Pulmonary infection
Randomized controlled trial
RCTrandomized controlled trial
S-proteinspike protein
SARS-CoV-2severe acute respiratory syndrome coronavirus 2
SEMA3Asemaphorin 3 A
semaphorin 3 A
severe acute respiratory syndrome coronavirus 2
sialyl Lewis X
signal transducer and activator of transcription 3
SLeXsialyl Lewis X
Spike protein
spread of COVID-19
STAT3signal transducer and activator of transcription 3
stem cell
TGF-β1transforming growth factor β1
TGFBR1transforming growth factor β receptor I
Therapies
therapy
tissue regeneration
TLR4toll-like receptors 4
TMPRSS2transmembrane protease serine protease 2
TNFTumor Necrosis Factor
toll-like receptors 4
transforming growth factor β receptor I
transforming growth factor β1
transmembrane protease serine protease 2
tumor necrosis factor
utility
Vaccine
Vaccines
vascular cell adhesion molecule
vascular endothelial growth factor
VCAMvascular cell adhesion molecule
VEGFvascular endothelial growth factor
[DOI] 10.1016/j.phrs.2022.106334 [Article Type] Review article
[DOI] 10.1016/j.phrs.2022.106334 [Article Type] Review article
Immunomodulation of Mesenchymal Stem Cells in Acute Lung Injury: From Preclinical Animal Models to Treatment of Severe COVID-19
급성 폐 손상에서 중간엽 줄기 세포의 면역 조절: 전임상 동물 모델에서 중증 COVID-19 치료까지
Review
Published on
Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 변종,
Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 변종,
[키워드] acute lung injury
acute respiratory distress
acute respiratory distress syndrome
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
animal
animal model
antiviral properties
antiviral property
caused
Cell
Cell therapy
clinical trial
clinical trials
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
Cytokine storm
highlight
immunomodulation
immunomodulatory
Infection
lung
Lung injury
mass
Mesenchymal stem cells
Model
Mortality
MSC
MSC therapy
MSCs
outcome
pandemic
Pathogenesis
patients with COVID-19
potential mechanism
potential mechanisms
Preclinical
public health
Reinfection
respiratory distress
Respiratory distress syndrome
risk
SARS-CoV-2
SARS-COV-2 infection
severe acute respiratory syndrome Coronavirus
STEM
stem cells
syndrome
the SARS-CoV-2
tissue repair
treat
vaccination
vaccine breakthrough infection
vaccine breakthrough infections
Viral variants
[DOI] 10.3390/ijms23158196 PMC 바로가기 [Article Type] Review
[DOI] 10.3390/ijms23158196 PMC 바로가기 [Article Type] Review
Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models
SARS-CoV-2에 대한 결합된 근육내/비강내 RAZI-COV PARS 백신 후보의 안전성 및 효능: 여러 동물 모델에서의 전임상 연구
Article
[키워드] absence
adjuvant
administration
Against
Amino acid
animal
approval
BALB/c mice
blood chemistry
candidate
candidate vaccine
Cellular immune response
changes in
clearance
Combined
control group
COVID-19
different dose
dose
Efficacy
Efficacy and safety
evaluated
hamster
hamsters
heterologous prime-boost
High dose
humoral
IgA antibody
immune
immune response
Immunity
induce
interval
intramuscular
intranasal
intranasally
Iran
lung
Lung pathology
Lungs
mice
middle
Model
Modification
monomeric
mucosal
N-terminal domain
Neutralizing antibodies
New
NTD
organs
parameters
Pathological examination
pfu
Placebo
Preclinical
Protective
RAZI-COV PARS
RBD
regimens
repeated
robust
Safety
SARS-CoV-2
SARS-CoV-2 preclinical study
SARS-CoV-2 spike protein
significantly
specific IgG antibody
Spike protein
Spread
stimulated
subunits
tested
the vaccine
trimer
vaccination
Vaccine
vaccine candidate
viral infection
virus
virus load
was performed
[DOI] 10.3389/fimmu.2022.836745 PMC 바로가기 [Article Type] Article
[DOI] 10.3389/fimmu.2022.836745 PMC 바로가기 [Article Type] Article
Preclinical trial of noncontact anthropometric measurement using IR-UWB radar
Research
[키워드] Algorithm
Analysis
BMI
body mass index
children
CNN
disorders
enrolled
estimate
feasibility
growth
healthy
Infant
Infectious disease
Intraclass correlation coefficient
Malnutrition
Medical conditions
obesity
parameter
Preclinical
predicted
profile
Support
Transmission
Trial
[DOI] 10.1038/s41598-022-12209-1 [Article Type] Research
[DOI] 10.1038/s41598-022-12209-1 [Article Type] Research
Preclinical Assessment of IgY Antibodies Against Recombinant SARS-CoV-2 RBD Protein for Prophylaxis and Post-Infection Treatment of COVID-19
COVID-19의 예방 및 감염 후 치료를 위한 재조합 SARS-CoV-2 RBD 단백질에 대한 IgY 항체의 전임상 평가
Article
[키워드] administration
Against
antibody
approach
assessment
COVID-19
COVID-19 infection
COVID-19 pandemic
death
demonstrated
develop
Efficacy
egg-yolk antibodies
hamster
histopathological
IgY
immunoreactivity
infected patients
intranasally
Mortality
neutralization
outbreak
pandemic
passive immunity
passive immunization
performed
Post-infection
Preclinical
produced
prophylactic treatment
protective effect
purified
Receptor binding domain
recombinant
recombinant RBD protein
Safety
SARS-CoV-2
SARS-CoV-2 RBD
therapy
Treatment
Vaccine
was tested
[DOI] 10.3389/fimmu.2022.881604 PMC 바로가기 [Article Type] Article
[DOI] 10.3389/fimmu.2022.881604 PMC 바로가기 [Article Type] Article